skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Treatment with a GnRH analogue: effects on hemostatic risk factors for thrombo-embolic disease

Lindoff, C ; Petersson, F ; Samsioe, G ; Astedt, B

International journal of fertility and menopausal studies, 1994-05, Vol.39 (3), p.133

United States

Sem texto completo

Citações Citado por
  • Título:
    Treatment with a GnRH analogue: effects on hemostatic risk factors for thrombo-embolic disease
  • Autor: Lindoff, C ; Petersson, F ; Samsioe, G ; Astedt, B
  • Assuntos: Adult ; Antithrombin III - analysis ; Endometriosis - blood ; Endometriosis - drug therapy ; Estradiol - blood ; Factor VII - analysis ; Female ; Fibrinogen - analysis ; Goserelin - adverse effects ; Goserelin - therapeutic use ; Hemostasis - drug effects ; Humans ; Middle Aged ; Plasminogen Activator Inhibitor 1 - blood ; Plasminogen Activators - blood ; Protein C - analysis ; Risk Factors ; Thromboembolism - epidemiology ; Thromboembolism - etiology
  • É parte de: International journal of fertility and menopausal studies, 1994-05, Vol.39 (3), p.133
  • Descrição: Steroid hormones, especially estrogens, are known to affect hemostatic risk factors for thromboembolism, cardiovascular disease, and stroke. We examined these risk factors during depression of the serum estradiol concentration by a GnRH analogue. Patients were treated with a GnRH analogue, goserelin (Zoladex), 3.6 mg/inj monthly, for a period of 6 months. Blood samples were collected during and after treatment and in a control group. In ten patients a blood sample was also drawn before treatment. Measurements were made of serum estradiol, and the plasma concentrations of tissue-type plasminogen activator (t-PA) antigen, plasminogen activator inhibitor (PAI-1) antigen, antithrombin III (AT III) and protein C activity, factor VII (FVII) antigen, and fibrinogen. Outpatient clinics at the Departments of Obstetrics and Gynecology at two university hospitals in southern Sweden. Twenty-seven women with endometriosis were consecutively included. A control group comprised 20 women with normal menstrual cycles. The concentrations of the hemostatic components during depression of the serum estradiol concentrations, as compared to those during normal ovulatory cycles. Serum estradiol concentrations during treatment were comparable to those of postmenopausal women (mean, 23.2 pmol/L), and both AT III and protein C activity were significantly increased (P < .005 and P < .02, respectively). As compared to controls, plasma concentrations of PAI-1 and t-PA of patients were significantly higher both during and after treatment. In the subgroup also studied prior to treatment, there were no differences in hemostatic components, when comparing pretreatment and posttreatment values. Treatment with this type of GnRH analogue for 6 months is safe with regard to its effect on hemostatic risk factors. The similar responses of t-PA and its inhibitor, PAI-1, to alterations in estrogen levels as well as inflammatory reactivity presumably constitute a balance mechanism preserving fibrinolytic defenses.
  • Editor: United States
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.